Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents No significant financial relationships to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback